TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3063286

Group type: EXPERIMENTAL
Intervention: captopril (75 mg/d)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: canrenoate potassium (200 mg/d)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: atenolol (100 mg/d)
Number of subjects: 30
Study: 31936727

Group type: EXPERIMENTAL
Intervention: CrM-HMB group (0.04 g/kg/day of CrM plus 3 g/day of HMB)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: CrM-HMB group
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo group (PLG)
Number of subjects: 28

Group type: COMPARATOR
Intervention: CrM group (0.04 g/kg/day of CrM)
Number of subjects: 28

Group type: COMPARATOR
Intervention: HMB group (3 g/day of HMB)
Number of subjects: 28
Study: 29531290

Group type: EXPERIMENTAL
Intervention: Bedtime ingestion of hypertension medications (n=1037)
Number of subjects: 2078

Group type: COMPARATOR
Intervention: Morning ingestion of hypertension medications (n=1041)
Number of subjects: 2078
Study: 27365521

Group type: EXPERIMENTAL
Intervention: Professional oral care (teeth surface cleaning, scaling, and tongue cleaning weekly for 8 weeks)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control (brushing teeth and gargling with 0.9% sodium chloride solution or water)
Number of subjects: 200
Study: 25040447

Group type: EXPERIMENTAL
Intervention: Financial education and support programme plus nicotine replacement therapy (NRT) for 8 weeks
Number of subjects: 1046

Group type: COMPARATOR
Intervention: Nicotine replacement therapy (NRT) for 8 weeks plus Quitline support
Number of subjects: 1046
Study: 22936100

Group type: EXPERIMENTAL
Intervention: Facilitation of a recent target after fixating on a target (cricket ball) among semantically related distracters in Experiment 1.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Using silhouettes of objects for selection based on feature shape in Experiment 2.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Using silhouettes of animals with distracters of low target-shape similarity in Experiment 3.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Introducing a distracter with the target in the probe display in Experiments 4 and 5.
Number of subjects: 0
Study: 21197854

Group type: EXPERIMENTAL
Intervention: Caffeinated energy drink (5.0 mg caffeine/kg bodyweight)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Caffeine-free energy drink
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Caffeinated energy drink
Number of subjects: 8
Study: 18451643

Group type: EXPERIMENTAL
Intervention: Vitamin E-coated membrane (VE)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Reference polysulfone (PS) membrane
Number of subjects: 62
Study: 16758942

Group type: EXPERIMENTAL
Intervention: Fraxiparin (low molecular-weight heparin) administered before surgery
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Fraxiparin (low molecular-weight heparin) administered after surgery
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Preoperative preventive treatment with Fraxiparin
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Thromboprophylaxis prolonged for at least one month
Number of subjects: 152
Study: 12676037

Group type: EXPERIMENTAL
Intervention: Usual postoperative care plus massage therapy
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Usual postoperative care plus vibration therapy
Number of subjects: 105

Group type: COMPARATOR
Intervention: Usual postoperative care (UC)
Number of subjects: 105
Study: 11104859

Group type: EXPERIMENTAL
Intervention: Verbal problem-solving remediation
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo instruction
Number of subjects: 28
Study: 9175116

Group type: EXPERIMENTAL
Intervention: MIP-1 alpha positive glial cells in white matter
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: MIP-1 alpha positive neurons and glial cells in cortex
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: MIP-1 alpha mRNA expression
Number of subjects: 13
Study: 7967328

Group type: EXPERIMENTAL
Intervention: Oral aspirin (165 mg once daily)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of heparin (1,000 units per hour)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 94
Study: 3981166

Group type: EXPERIMENTAL
Intervention: 150 mg dose of metoprolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30057059

Group type: EXPERIMENTAL
Intervention: Laughter Yoga (LY)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Comedy Movie (spontaneous laughter)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Reading a Book
Number of subjects: 120
Study: 27018419

Group type: EXPERIMENTAL
Intervention: Gabapentin 250 mg
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Diphenhydramine citrate 76 mg
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Triazolam 0.5 mg
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 24840585

Group type: EXPERIMENTAL
Intervention: Participants with GH injuries during bow-and-arrow exercise
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Participants with GH injuries during external-rotation-with-scapular-squeeze exercise
Number of subjects: 39

Group type: COMPARATOR
Intervention: Healthy control participants during bow-and-arrow exercise
Number of subjects: 39

Group type: COMPARATOR
Intervention: Healthy control participants during external-rotation-with-scapular-squeeze exercise
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Participants with GH injuries during lawnmower exercise
Number of subjects: 39

Group type: COMPARATOR
Intervention: Healthy control participants during lawnmower exercise
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Participants with GH injuries during robbery exercise
Number of subjects: 39

Group type: COMPARATOR
Intervention: Healthy control participants during robbery exercise
Number of subjects: 39
Study: 22305276

Group type: EXPERIMENTAL
Intervention: Curcuminoids (2000mg/day)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Curcuminoids (6000mg/day)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Curcuminoids (varied doses)
Number of subjects: 53
Study: 20202684

Group type: EXPERIMENTAL
Intervention: 0.5 microg/day fluocinolone acetonide intravitreal insert
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 0.2 microg/day fluocinolone acetonide intravitreal insert
Number of subjects: 37
Study: 17888192

Group type: EXPERIMENTAL
Intervention: Hyperbaric bupivacaine (Group A)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Hyperbaric bupivacaine + 10 mL saline epidurally (Group B)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Plain bupivacaine (Group C)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Plain bupivacaine + 10 mL saline epidurally (Group D)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control group (Group A and B)
Number of subjects: 240
Study: 15987848

Group type: EXPERIMENTAL
Intervention: 1000 mg Ascorbic Acid (AA) twice daily for 6 days
Number of subjects: 48

Group type: COMPARATOR
Intervention: No Ascorbic Acid (AA) for 6 days
Number of subjects: 48
Study: 12622584

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (INO) 80 ppm with 21% final concentration of inspired oxygen (n=10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (21% inspired oxygen; n=10)
Number of subjects: 20
Study: 10582983

Group type: EXPERIMENTAL
Intervention: Citicoline (500 mg po daily) for 6 weeks
Number of subjects: 394

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 394
Study: 8915035

Group type: EXPERIMENTAL
Intervention: Donepezil 5 mg/day
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Donepezil (1, 3, or 5 mg)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study: 1801536

Group type: EXPERIMENTAL
Intervention: Selegiline
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 6188770

Group type: EXPERIMENTAL
Intervention: Local terbutaline (nontoxic doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (antigen challenge without terbutaline)
Number of subjects: 0
Study: 30267032

Group type: EXPERIMENTAL
Intervention: ISA 101 vaccine (100 μg/peptide) given subcutaneously on days 1, 22, and 50; Nivolumab (3 mg/kg) given intravenously every 2 weeks starting day 8 for up to 1 year
Number of subjects: 24
Study: 29294223

Group type: EXPERIMENTAL
Intervention: Initial catheter placement
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Last CT prior to randomization
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Catheter placement accuracy
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Non-operating room catheter placement
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Pre-admission use of antiplatelet drugs
Number of subjects: 500
Study: 26724834

Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid (ATRA) during induction and/or maintenance therapy
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid (ATRA)
Number of subjects: 240
Study: 24316679

Group type: EXPERIMENTAL
Intervention: NeReBot therapy (robotic training 35% of exercise time) + standard therapy (65% of exercise time)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Standard therapy for the upper limb (control group)
Number of subjects: 34
Study: 22584796

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (50 mg intravenously four times daily) and fludrocortisone (50 μg orally once daily)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Hydrocortisone and fludrocortisone
Number of subjects: 299
Study: 20172512

Group type: COMPARATOR
Intervention: Conventional TESE
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Microdissection TESE
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 335
Study: 18001380

Group type: EXPERIMENTAL
Intervention: Probiotic yogurt
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional yogurt
Number of subjects: 0
Study: 15149708

Group type: EXPERIMENTAL
Intervention: 3-week cognitive-behavioral group intervention
Number of subjects: 23

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 23
Study: 11771665

Group type: EXPERIMENTAL
Intervention: Letrozole (aromatase inhibitor) for 6 months
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 42
Study: 9659199

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 8131700

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg once a day for 5 days
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Enprostil 35 micrograms three times a day for 5 days
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Combination of omeprazole and enprostil
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 2563786

Group type: EXPERIMENTAL
Intervention: Low sodium intake group (53 subjects; diet containing less than 80 mmol sodium/day plus 8 placebo tablets daily)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Normal sodium intake group (55 subjects; same dietary sodium plus 8 slow-release sodium chloride [10 mmol] tablets daily)
Number of subjects: 111
Study: 31513759

Group type: EXPERIMENTAL
Intervention: Wahakura (a bassinet-like device made of native flax)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pēpi-Pod (related safe sleep device)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable (general intervention context)
Number of subjects: 0
Study: 27821375

Group type: EXPERIMENTAL
Intervention: Absorb everolimus-eluting bioresorbable vascular scaffold (BVS)
Number of subjects: 384

Group type: COMPARATOR
Intervention: Cobalt-chromium everolimus-eluting stent (CoCr-EES)
Number of subjects: 384
Study: 26180559

Group type: EXPERIMENTAL
Intervention: donepezil
Number of subjects: 130

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 130
Study: 24280617

Group type: EXPERIMENTAL
Intervention: Intradermal injection of botulinum toxin A (BoNT/A)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Microneedle fractional radiofrequency (MFR) therapy
Number of subjects: 12

Group type: COMPARATOR
Intervention: Untreated skin
Number of subjects: 12

Group type: COMPARATOR
Intervention: BoNT/A injection side
Number of subjects: 12
Study: 21680997

Group type: EXPERIMENTAL
Intervention: Irbesartan/HCTZ (150 mg/12.5 mg titrated to 300 mg/25 mg)
Number of subjects: 1268

Group type: COMPARATOR
Intervention: Irbesartan (150 mg titrated to 300 mg)
Number of subjects: 1268

Group type: EXPERIMENTAL
Intervention: Irbesartan/HCTZ
Number of subjects: 1268

Group type: COMPARATOR
Intervention: Irbesartan
Number of subjects: 1268

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 1268
Study: 18804918

Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 297
Study: 15940534

Group type: EXPERIMENTAL
Intervention: Simulated altitude (2,650 m)
Number of subjects: 14
Study: 10483629

Group type: EXPERIMENTAL
Intervention: Imagery
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Yoga stretching
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control
Number of subjects: 114
Study: 8597317

Group type: EXPERIMENTAL
Intervention: lovastatin, 80 mg/d
Number of subjects: 188

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 188
Study: 1822427

Group type: EXPERIMENTAL
Intervention: Full inpatient treatment
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Day center treatment
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Walk-in clinic treatment
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Hysterical syndrome
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Psychasthenic syndrome
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Overall evaluation of the therapeutic programmes
Number of subjects: 266
Study: 6752585

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU)
Number of subjects: 38

Group type: COMPARATOR
Intervention: mitomycin C
Number of subjects: 38
Study: 30870040

Group type: EXPERIMENTAL
Intervention: Muscle Power Training (MPT)
Number of subjects: 12
Study: 31595295

Group type: EXPERIMENTAL
Intervention: Oily fish consumption (∼300 g/wk)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Poultry consumption (control group)
Number of subjects: 199
Study: 28871896

Group type: EXPERIMENTAL
Intervention: Self-guided intervention
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Supported-guided intervention
Number of subjects: 194
Study: 26830711

Group type: EXPERIMENTAL
Intervention: 7-week simulation curriculum (Group A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 7-week lecture curriculum (Group B)
Number of subjects: 0
Study: 24702572

Group type: EXPERIMENTAL
Intervention: Femtosecond laser-assisted cataract surgery
Number of subjects: 104

Group type: COMPARATOR
Intervention: Standard phacoemulsification
Number of subjects: 104
Study: 22938185

Group type: EXPERIMENTAL
Intervention: Individualized, discrete event simulations
Number of subjects: 11
Study: 20124504

Group type: EXPERIMENTAL
Intervention: Generalized special nursery placement
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Special nursery placement solely for children with ASDs
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Home-based 1:1 programme
Number of subjects: 33
Study: 17950797

Group type: EXPERIMENTAL
Intervention: Coenzyme Q(10) (200 mg/day)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 15766818

Group type: EXPERIMENTAL
Intervention: Perindopril (2 to 4 mg/day)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 11990868

Group type: EXPERIMENTAL
Intervention: Interferon beta-1a (Rebif-Serono)
Number of subjects: 52
Study: 10557167

Group type: EXPERIMENTAL
Intervention: Fluoride drops (0.25 mg for 2-3 year-olds, 0.5 mg for older children) taken daily for 3 years
Number of subjects: 176

Group type: COMPARATOR
Intervention: Control group (no fluoride drops)
Number of subjects: 176
Study: 8575054

Group type: EXPERIMENTAL
Intervention: Alcuronium (0.3 mg/kg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pancuronium (0.1 mg/kg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Alcuronium and Pancuronium
Number of subjects: 40
Study: 2199681

Group type: EXPERIMENTAL
Intervention: Tamoxifen (10 mg twice a day)
Number of subjects: 140
Study: 31932574

Group type: EXPERIMENTAL
Intervention: Porous polyoxymethylene thermoplastic regulator combined with a 3D printed template
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional PPSF
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 31106415

Group type: EXPERIMENTAL
Intervention: Child Friendly Spaces (CFS) attendance
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Child Friendly Spaces (CFS) attendance (higher quality programming)
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Child Friendly Spaces (CFS) attendance (higher quality programming for boys)
Number of subjects: 430

Group type: COMPARATOR
Intervention: CFS attendance
Number of subjects: 430
Study: 28213908

Group type: EXPERIMENTAL
Intervention: Lacosamide (LCM) 400 mg at a rate of 60 mg/kg/min
Number of subjects: 66
Study: 25727903

Group type: EXPERIMENTAL
Intervention: High in milk diet
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: High in cheese diet
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 15
Study: 24164102

Group type: EXPERIMENTAL
Intervention: Zoledronic acid treatment
Number of subjects: 60
Study: 22288723

Group type: EXPERIMENTAL
Intervention: Diode laser transscleral cyclophotocoagulation (TSCP)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control eyes (untreated)
Number of subjects: 8
Study: 20070800

Group type: EXPERIMENTAL
Intervention: Problem-Based Learning (PBL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single PBL intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple PBL interventions
Number of subjects: 0
Study: 17557777

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study: 16386537

Group type: EXPERIMENTAL
Intervention: Folic acid (10 mg) and vitamin B12 (500 mg) daily for 3 months
Number of subjects: 70
Study: 12048040

Group type: EXPERIMENTAL
Intervention: 10mg/kg of phenytoin
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 10461765

Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.2 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Terazosin (1 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Lactate capsule (Control)
Number of subjects: 10
Study: 7609265

Group type: EXPERIMENTAL
Intervention: Monoclonal antiendotoxin antibody
Number of subjects: 100
Study: 2507435

Group type: EXPERIMENTAL
Intervention: Metoclopramide (MCP, 10 mg orally 3 times daily for 7 days)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (untreated LP)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Metoclopramide (MCP)
Number of subjects: 24
Study: 324556

Group type: EXPERIMENTAL
Intervention: Cephaloridine (1 g in 2 ml of water)
Number of subjects: 410

Group type: COMPARATOR
Intervention: Ampicillin (1 g in 2 ml of water)
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Cephaloridine
Number of subjects: 410

Group type: COMPARATOR
Intervention: Ampicillin
Number of subjects: 410
Study: 31332655

Group type: EXPERIMENTAL
Intervention: Lung ultrasound-guided therapy (semi-quantitative evaluation of B lines and the presence of pleural effusion)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional treatment (clinical assessment of congestion)
Number of subjects: 0
Study: 28395844

Group type: EXPERIMENTAL
Intervention: Co-trimoxazole (100 mg/20 mg once daily until age 6 months and 200 mg/40 mg once daily thereafter)
Number of subjects: 2848

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2848

Group type: EXPERIMENTAL
Intervention: Co-trimoxazole
Number of subjects: 2848
Study: 26057427

Group type: EXPERIMENTAL
Intervention: 2-day hospice experience
Number of subjects: 61
Study: 23075046

Group type: EXPERIMENTAL
Intervention: Hyperbaric articaine 72 mg with fentanyl 10 μg (Group A + F)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Hyperbaric articaine 72 mg without fentanyl (Group A)
Number of subjects: 100
Study: 22122992

Group type: EXPERIMENTAL
Intervention: Memantine treatment
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 19317864

Group type: EXPERIMENTAL
Intervention: 0.125% levobupivacaine infused at 8.4 ml/h (low concentration group, n=35)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 0.75% levobupivacaine infused at 1.4 ml/h (high concentration group, n=35)
Number of subjects: 70
Study: 17369566

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (4 mg intravenously on day 1 only)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 15479682

Group type: EXPERIMENTAL
Intervention: Probiotic Escherichia coli Nissle 1917, 200 mg once daily (n = 162)
Number of subjects: 327

Group type: COMPARATOR
Intervention: Mesalazine, 500 mg three times daily (n = 165)
Number of subjects: 327
Study: 11903415

Group type: EXPERIMENTAL
Intervention: Metformin (850 mg b.i.d.)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 9390616

Group type: EXPERIMENTAL
Intervention: Propofol 1% in new formulation
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard propofol formulation
Number of subjects: 24
Study: 8201393

Group type: EXPERIMENTAL
Intervention: Audiotape of the consultation followed 7 to 10 days later by the letter
Number of subjects: 182

Group type: COMPARATOR
Intervention: Individualized summary letters followed by the audiotape
Number of subjects: 182
Study: 3310725

Group type: EXPERIMENTAL
Intervention: Halothane in 30% O2/70% N2
Number of subjects: 40

Group type: COMPARATOR
Intervention: Halothane in 30% O2/70% N2O
Number of subjects: 40
Study: 31810405

Group type: EXPERIMENTAL
Intervention: Thoracic manipulation, education, and exercise
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sham manipulation, education, and exercise
Number of subjects: 90
Study: 29382251

Group type: EXPERIMENTAL
Intervention: Doxycycline treatment for nodding syndrome
Number of subjects: 0
Study: 26975947

Group type: EXPERIMENTAL
Intervention: Cavit
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: IRM
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: CLIP
Number of subjects: 60